Evolution of mNGS in Clinical Microbiology: 5 Key Shifts
Clinical microbiology laboratories face a persistent problem: culture-based diagnostics — the backbone of pathogen identification for over a century — miss critical infections in the patients who need answers most. Metagenomic next-generation sequencing (mNGS) in clinical microbiology is now emerging as a transformative complement to conventional methods, particularly for ICU patients with severe sepsis and pneumonia. In this symposium talk, Prof. Dr. Po Ren Hsueh traces the evolution of diagnostic microbiology from culture to syndromic panels to broad-range sequencing, drawing on decades of clinical experience at the China Medical University Hospital in Taiwan.
Key Takeaways
- Conventional blood culture detects pathogens in only a fraction of severe sepsis cases, while mNGS consistently identifies additional organisms — including polymicrobial infections that culture misses entirely.
- Multiplex PCR panels (meningitis, pneumonia, blood culture ID, GI) accelerated turnaround but remain limited to pre-selected targets, missing unexpected or rare pathogens.
- mNGS from blood samples frequently detects 3–8 organisms per sample compared to 1–2 from conventional culture, presenting new interpretation challenges.
- Host depletion is critical for blood and respiratory specimens where human DNA dominates the sequencing output.
- Clinical adoption requires standardized reporting guidelines and diagnostic stewardship committees to translate metagenomic results into actionable treatment decisions.
From Culture Plates to Syndromic Panels — The Diagnostic Timeline
Conventional Culture and Its Limitations
The diagnostic workflow for infectious disease has followed a well-established path for decades: collect the clinical specimen, inoculate culture media, wait two to three days for colony growth, then identify organisms using biochemical tests or matrix-assisted laser desorption/ionization (MALDI-TOF) mass spectrometry. This conventional pipeline remains the backbone of most clinical microbiology laboratories worldwide.
Prof. Hsueh highlighted a critical limitation of this approach: antimicrobial resistance (AMR) is rising across Asia, particularly in ICU settings in Taiwan, making rapid pathogen identification and resistance profiling essential for appropriate antimicrobial stewardship. Culture-based methods simply cannot deliver results fast enough to guide early therapeutic decisions in critically ill patients. The two-to-three day turnaround leaves clinicians prescribing empiric broad-spectrum antibiotics — a practice that contributes to further resistance selection.
The Multiplex PCR Era
The introduction of syndromic multiplex PCR panels represented a major step forward. Prof. Hsueh described five panels in clinical use at his institution: a meningitis panel, a pneumonia panel, a blood culture identification panel, a gastrointestinal panel, and a positive blood culture panel. The pneumonia panel alone detects 30 bacterial and viral targets plus eight antimicrobial resistance genes, delivering results within hours rather than days.
However, these panels have an inherent ceiling: they only detect what they are designed to find. In meningitis diagnostics, for example, Prof. Hsueh noted that regionally important pathogens such as Japanese encephalitis virus and certain spirochetes are absent from standard panel configurations, leading to diagnostic blind spots in areas where these infections are endemic.
Where Clinical Metagenomics Fills the Gap
Metagenomic sequencing removes the hypothesis-dependent constraint of panel-based testing. Rather than querying a fixed list of targets, mNGS captures all nucleic acid in a sample — bacterial, fungal, viral, and parasitic — providing an unbiased view of the microbial landscape.
Prof. Hsueh presented landmark examples of this capability, including the initial identification of SARS-CoV-2 in early 2020 through metagenomic analysis, and the diagnosis of central nervous system (CNS) infections where all conventional methods returned negative results. In one published case, a patient with severe meningitis underwent extensive microbiological workup including brain biopsy — all negative — before mNGS identified the causative pathogen from cerebrospinal fluid (CSF).
For sepsis patients specifically, broad-range metagenomic sequencing from blood consistently detects more pathogens than conventional blood culture. In a 50-patient sepsis cohort at Prof. Hsueh’s institution, mNGS detected multiple organisms per sample (ranging from 1 to 8 per patient) compared to just 1–2 from blood culture, revealing polymicrobial infections that culture completely missed.
Real-World ICU Cases — What mNGS Reveals Beyond Culture
Prof. Hsueh presented three ICU cases illustrating the interpretive complexity of metagenomic results:
Case 1: A 42-year-old cancer patient with stage IV disease, pneumonia, and respiratory failure. Blood culture grew limited organisms, while mNGS detected additional bacteria and viruses. The metagenomic profile was concordant with culture results but provided a more complete picture that informed combination therapy.
Case 2: A 49-year-old patient where mNGS detected gram-negative anaerobic bacteria present in both respiratory and oral specimens, suggesting aspiration pneumonia — a clinical inference that culture alone could not support. The metagenomic data added pathogenesis context, not just pathogen identity.
Case 3: An 85-year-old man with severe community-acquired pneumonia where mNGS identified multiple organisms, creating a clinical dilemma: which pathogen to prioritize for targeted treatment. This case underscored that more data is not automatically better — it requires expert interpretation through diagnostic stewardship.
Integrating Metagenomic Sequencing into Clinical Guidelines
Prof. Hsueh emphasized that the clinical adoption of mNGS requires more than technical validation. His institution has developed internal guidelines for classifying and interpreting metagenomic results, including algorithms for assessing the strength of correlation between detected organisms and clinical disease.
Key unresolved challenges include: determining which patients should receive mNGS testing (given the multi-day turnaround and cost), establishing clinical interpretation frameworks for polymicrobial results, and defining the role of clinical microbiologists as sequence interpreters alongside infectious disease physicians.
Host DNA depletion was identified as a critical preprocessing step, especially for blood and respiratory specimens where human DNA can overwhelm microbial signal. Technologies such as the Devin host depletion filter address this bottleneck by physically removing human cells before DNA extraction, enriching the microbial fraction available for sequencing. Prof. Hsueh also noted that RNA-based metagenomic approaches (metatranscriptomics) offer complementary pathogen detection and resistance marker identification, representing the next frontier for clinical laboratories.
From a therapeutic perspective, Prof. Hsueh expressed optimism that mNGS will increasingly serve as a front-line diagnostic tool for detecting difficult-to-culture and unexpected pathogens — precisely the cases where conventional methods fail and where rapid identification most impacts patient outcomes.
About the Speaker
Prof. Dr. Po Ren Hsueh is a leading clinical microbiologist at the China Medical University Hospital in Taiwan. His research spans antimicrobial resistance surveillance, diagnostic microbiology, and the clinical application of metagenomic sequencing for infectious disease diagnosis.
